Cargando…
Reversibility of Vasalgel™ male contraceptive in a rabbit model
BACKGROUND: Development of a non-hormonal long-acting reversible contraceptive for men could have a significant impact on reducing unintended pregnancies. Vasalgel™ is a high molecular weight polymer consisting of styrene-alt-maleic acid (SMA) dissolved in dimethyl sulfoxide being developed as a rev...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381074/ https://www.ncbi.nlm.nih.gov/pubmed/28417005 http://dx.doi.org/10.1186/s12610-017-0051-1 |
_version_ | 1782519865647562752 |
---|---|
author | Waller, Donald Bolick, David Lissner, Elaine Premanandan, Christopher Gamerman, Gary |
author_facet | Waller, Donald Bolick, David Lissner, Elaine Premanandan, Christopher Gamerman, Gary |
author_sort | Waller, Donald |
collection | PubMed |
description | BACKGROUND: Development of a non-hormonal long-acting reversible contraceptive for men could have a significant impact on reducing unintended pregnancies. Vasalgel™ is a high molecular weight polymer consisting of styrene-alt-maleic acid (SMA) dissolved in dimethyl sulfoxide being developed as a reversible male contraceptive device. It forms a hydrogel when implanted into the vasa deferentia, which prevents the passage of sperm. Previous studies in the rabbit have proven its efficacy, durability and rapid onset. This study evaluates the capacity to restore sperm concentrations in ejaculates after a reversal procedure. METHODS: Sodium bicarbonate was injected into the vasa deferentia after fourteen months of azoospermia following the injection of two device variations (Vasalgel 100 and Vasalgel 80). Semen samples were then collected for six months and sperm characteristics were compared to baseline levels. Samples of vasa deferentia were obtained for histological examination. RESULTS: Spermatozoa were present in all subject ejaculates after the reversal procedure. Sperm concentration and sperm motility were similar to baseline levels after reversal, while sperm forward progression was significantly lower and normal acrosomes were not observed. Forward progression percentages increased linearly during six months of semen collection, however, normal acrosomes were not observed at the conclusion of the study. Histologically, several vasa deferentia were clear of the device and contained an intact epithelial lining. A smaller proportion of tissues contained residual test material. A secondary intraluminal inflammatory response was seen occasionally in the tissues containing residual material. There was no difference between the two device variations for studied parameters. CONCLUSIONS: Vasalgel’s prevention of sperm transport for 14 months was reversed through an intravasal injection of sodium bicarbonate. Post-reversal sperm concentrations and motility returned to baseline levels during the six-month follow up. Residual material in the vas lumen or compromised epididymal and vas deferens function may be resulting in reduced forward progression and loss of acrosomes during transit through the vas. Reduced forward progression and the lack of normal acrosomes strongly suggest impaired sperm function. |
format | Online Article Text |
id | pubmed-5381074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53810742017-04-17 Reversibility of Vasalgel™ male contraceptive in a rabbit model Waller, Donald Bolick, David Lissner, Elaine Premanandan, Christopher Gamerman, Gary Basic Clin Androl Research Article BACKGROUND: Development of a non-hormonal long-acting reversible contraceptive for men could have a significant impact on reducing unintended pregnancies. Vasalgel™ is a high molecular weight polymer consisting of styrene-alt-maleic acid (SMA) dissolved in dimethyl sulfoxide being developed as a reversible male contraceptive device. It forms a hydrogel when implanted into the vasa deferentia, which prevents the passage of sperm. Previous studies in the rabbit have proven its efficacy, durability and rapid onset. This study evaluates the capacity to restore sperm concentrations in ejaculates after a reversal procedure. METHODS: Sodium bicarbonate was injected into the vasa deferentia after fourteen months of azoospermia following the injection of two device variations (Vasalgel 100 and Vasalgel 80). Semen samples were then collected for six months and sperm characteristics were compared to baseline levels. Samples of vasa deferentia were obtained for histological examination. RESULTS: Spermatozoa were present in all subject ejaculates after the reversal procedure. Sperm concentration and sperm motility were similar to baseline levels after reversal, while sperm forward progression was significantly lower and normal acrosomes were not observed. Forward progression percentages increased linearly during six months of semen collection, however, normal acrosomes were not observed at the conclusion of the study. Histologically, several vasa deferentia were clear of the device and contained an intact epithelial lining. A smaller proportion of tissues contained residual test material. A secondary intraluminal inflammatory response was seen occasionally in the tissues containing residual material. There was no difference between the two device variations for studied parameters. CONCLUSIONS: Vasalgel’s prevention of sperm transport for 14 months was reversed through an intravasal injection of sodium bicarbonate. Post-reversal sperm concentrations and motility returned to baseline levels during the six-month follow up. Residual material in the vas lumen or compromised epididymal and vas deferens function may be resulting in reduced forward progression and loss of acrosomes during transit through the vas. Reduced forward progression and the lack of normal acrosomes strongly suggest impaired sperm function. BioMed Central 2017-04-05 /pmc/articles/PMC5381074/ /pubmed/28417005 http://dx.doi.org/10.1186/s12610-017-0051-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Waller, Donald Bolick, David Lissner, Elaine Premanandan, Christopher Gamerman, Gary Reversibility of Vasalgel™ male contraceptive in a rabbit model |
title | Reversibility of Vasalgel™ male contraceptive in a rabbit model |
title_full | Reversibility of Vasalgel™ male contraceptive in a rabbit model |
title_fullStr | Reversibility of Vasalgel™ male contraceptive in a rabbit model |
title_full_unstemmed | Reversibility of Vasalgel™ male contraceptive in a rabbit model |
title_short | Reversibility of Vasalgel™ male contraceptive in a rabbit model |
title_sort | reversibility of vasalgel™ male contraceptive in a rabbit model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381074/ https://www.ncbi.nlm.nih.gov/pubmed/28417005 http://dx.doi.org/10.1186/s12610-017-0051-1 |
work_keys_str_mv | AT wallerdonald reversibilityofvasalgelmalecontraceptiveinarabbitmodel AT bolickdavid reversibilityofvasalgelmalecontraceptiveinarabbitmodel AT lissnerelaine reversibilityofvasalgelmalecontraceptiveinarabbitmodel AT premanandanchristopher reversibilityofvasalgelmalecontraceptiveinarabbitmodel AT gamermangary reversibilityofvasalgelmalecontraceptiveinarabbitmodel |